

# Kathleen J Claes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1681887/publications.pdf>

Version: 2024-02-01

49  
papers

1,477  
citations

304743

22  
h-index

330143

37  
g-index

49  
all docs

49  
docs citations

49  
times ranked

2485  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic Accuracy of Noninvasive Bone Turnover Markers in Renal Osteodystrophy. <i>American Journal of Kidney Diseases</i> , 2022, 79, 667-676.e1.	1.9	25
2	Natural History of Bone Disease following Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 638-652.	6.1	12
3	Guidelines for Genetic Testing and Management of Alport Syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 143-154.	4.5	49
4	Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy. <i>Journal of Clinical Oncology</i> , 2022, 40, 2447-2457.	1.6	36
5	Vascular calcification of the abdominal aorta has minimal impact on lumbar spine bone density in patients with chronic kidney disease. <i>Bone</i> , 2022, 162, 116482.	2.9	8
6	Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4. <i>Journal of Neurology</i> , 2021, 268, 923-935.	3.6	48
7	Hyperhomocysteinemia: a trigger for complement-mediated TMA?. <i>Acta Clinica Belgica</i> , 2021, 76, 65-69.	1.2	2
8	Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review. <i>Frontiers in Pharmacology</i> , 2021, 12, 630949.	3.5	9
9	Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria. <i>European Journal of Human Genetics</i> , 2021, 29, 1186-1197.	2.8	61
10	Factors influencing the long-term outcome of tunneled hemodialysis catheters. <i>Journal of Vascular Access</i> , 2021, , 112972982097626.	0.9	1
11	Patterns of renal osteodystrophy 1-yr after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2130-2139.	0.7	11
12	Pregnancy After Kidney Transplantation and Its Impact on Graft Function. <i>Transplantation</i> , 2021, Publish Ahead of Print, .	1.0	0
13	Static histomorphometry allows for a diagnosis of bone turnover in renal osteodystrophy in the absence of tetracycline labels. <i>Bone</i> , 2021, 152, 116066.	2.9	7
14	Seroprevalence of Antibodies against Diphtheria, Tetanus and Pertussis in Adult At-Risk Patients. <i>Vaccines</i> , 2021, 9, 18.	4.4	7
15	Strategies for asymmetrical triacetate dialyser heparin-free effective haemodialysis: the SAFE study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1901-1907.	2.9	10
16	Natural history of mineral metabolism, bone turnover and bone mineral density in de novo renal transplant recipients treated with a steroid minimization immunosuppressive protocol. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 697-705.	0.7	21
17	Discrepancies between bioimpedance spectroscopy devices in haemodialysis patients. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 906-908.	2.9	1
18	Vaccination coverage of recommended vaccines and determinants of vaccination in at-risk groups. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2136-2143.	3.3	32

#	ARTICLE	IF	CITATIONS
19	An international cohort study of autosomal dominant tubulointerstitial kidney disease due to mutations identifies distinct clinical subtypes. <i>Kidney International</i> , 2020, 98, 1589-1604.	5.2	27
20	P1064HEPARIN-FREE DIALYSIS: A PHASE II PILOT STUDY USING ASYMMETRIC TRIACETATE (ATA) CELLULOSE DIALYZERS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
21	Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients. <i>Kidney International Reports</i> , 2020, 5, 627-631.	0.8	13
22	Effect of an intervention on the congruence of nurses' and patients' perceptions of patient-centred care: A pre-test post-test study. <i>Journal of Evaluation in Clinical Practice</i> , 2020, 26, 1648-1656.	1.8	3
23	A distinct bone phenotype in ADPKD patients with end-stage renal disease. <i>Kidney International</i> , 2019, 95, 412-419.	5.2	23
24	Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients. <i>Kidney International</i> , 2019, 95, 1461-1470.	5.2	61
25	Multicenter, Randomized Trial of Conventional Balloon Angioplasty versus Paclitaxel-Coated Balloon Angioplasty for the Treatment of Dysfunctional Autologous Dialysis Fistulae. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 470-475.e3.	0.5	47
26	Belgian consensus statement on the diagnosis and management of patients with atypical hemolytic uremic syndrome. <i>Acta Clinica Belgica</i> , 2018, 73, 80-89.	1.2	12
27	Renal progression factors in young patients with tuberous sclerosis complex: a retrospective cohort study. <i>Pediatric Nephrology</i> , 2018, 33, 2085-2093.	1.7	29
28	Patient and treatment characteristics associated with patient activation in patients undergoing hemodialysis: a cross-sectional study. <i>BMC Nephrology</i> , 2018, 19, 126.	1.8	27
29	Clinical case report: a rare cause of acute kidney failure – tissue is the issue. <i>Acta Clinica Belgica</i> , 2017, 72, 201-204.	1.2	3
30	Decreased Circulating Sclerostin Levels in Renal Transplant Recipients With Persistent Hyperparathyroidism. <i>Transplantation</i> , 2016, 100, 2188-2193.	1.0	21
31	Microbiota-Derived Phenylacetylglutamine Associates with Overall Mortality and Cardiovascular Disease in Patients with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 3479-3487.	6.1	144
32	<i>Mycobacterium genavense</i> infection in a solid organ recipient: a diagnostic and therapeutic challenge. <i>Transplant Infectious Disease</i> , 2016, 18, 125-131.	1.7	17
33	Phosphorus metabolism in peritoneal dialysis- and haemodialysis-treated patients. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1508-1514.	0.7	32
34	The influence of renal transplantation on retained microbial human co-metabolites. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1721-1729.	0.7	35
35	Proteinuria as a Noninvasive Marker for Renal Allograft Histology and Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 281-292.	6.1	65
36	Microscopic nephrocalcinosis in chronic kidney disease patients. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 843-848.	0.7	17

#	ARTICLE	IF	CITATIONS
37	Invasive Aspergillosis After Kidney Transplant: Case-Control Study. <i>Clinical Infectious Diseases</i> , 2015, 60, 1505-1511.	5.8	38
38	Criteria for HNF1B analysis in patients with congenital abnormalities of kidney and urinary tract. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 835-842.	0.7	57
39	Hemodialysis Access-Induced Ischemia Is Not Related to Configuration and Access Flow Rates of Upper Arm Arteriovenous Fistulas at the Elbow. <i>Annals of Vascular Surgery</i> , 2015, 29, 682-689.	0.9	1
40	Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. <i>Kidney International</i> , 2015, 87, 210-216.	5.2	52
41	Associations of Soluble CD14 and Endotoxin with Mortality, Cardiovascular Disease, and Progression of Kidney Disease among Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1525-1533.	4.5	59
42	Heritability and Clinical Determinants of Serum Indoxyl Sulfate and p-Cresyl Sulfate, Candidate Biomarkers of the Human Microbiome Enterotype. <i>PLoS ONE</i> , 2014, 9, e79682.	2.5	28
43	Postimplantation X-ray parameters predict functional catheter problems in peritoneal dialysis. <i>Kidney International</i> , 2014, 86, 1001-1006.	5.2	13
44	The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. <i>Kidney International</i> , 2014, 85, 636-640.	5.2	106
45	Time course of asymmetric dimethylarginine and symmetric dimethylarginine levels after successful renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1965-1972.	0.7	10
46	Aortic calcifications and arterial stiffness as predictors of cardiovascular events in incident renal transplant recipients. <i>Transplant International</i> , 2013, 26, 973-981.	1.6	36
47	Sclerostin: Another Vascular Calcification Inhibitor?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3221-3228.	3.6	143
48	Impact of Vascular Calcification on Corrected QT Interval at the Time of Renal Transplantation. <i>American Journal of Nephrology</i> , 2012, 35, 24-30.	3.1	13
49	The Many Faces of Merlin. <i>Chest</i> , 2011, 140, 791-794.	0.8	5